{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:36:18Z","timestamp":1792571778866,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"22","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000268","name":"RCUK | Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/X008460\/1"],"award-info":[{"award-number":["BB\/X008460\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,6,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Breast cancer is characterised by profound genetic heterogeneity, with oestrogen receptor alpha (ER\u03b1, encoded by\n                    <jats:italic>ESR1<\/jats:italic>\n                    ) being a central driver in ~70% of cases. While point mutations in the ligand-binding domain of\n                    <jats:italic>ESR1<\/jats:italic>\n                    are well recognised mediators of endocrine resistance, a growing body of evidence highlights\n                    <jats:italic>ESR1<\/jats:italic>\n                    gene fusions as an emerging class of genomic alterations with important clinical implications. These rearrangements, predominantly arising from intrachromosomal events on chromosome 6, truncate the hormone-binding domain and fuse\n                    <jats:italic>ESR1<\/jats:italic>\n                    with diverse partners, producing constitutively active chimeric proteins. Recurrent fusions such as\n                    <jats:italic>ESR1\u2013CCDC170<\/jats:italic>\n                    ,\n                    <jats:italic>ESR1\u2013YAP1<\/jats:italic>\n                    , and\n                    <jats:italic>ESR1\u2013AKAP12<\/jats:italic>\n                    have been consistently associated with therapy resistance, metastatic progression, and poor clinical outcome, suggesting that they function as oncogenic drivers rather than incidental by-products of genomic instability. However, variability in oncogenic potential indicates that only a subset of fusions are biologically functional. Key determinants of functionality include reading-frame preservation, domain architecture, intrinsic disorder content, and the molecular features contributed by the partner gene, many of which encode transcription factors, signalling adaptors, or cytoskeletal regulators. Structural enrichment in intrinsically disordered regions and the potential for phase separation further implicate\n                    <jats:italic>ESR1<\/jats:italic>\n                    fusions in the formation of aberrant transcriptional condensates that amplify ER signalling. Importantly, while many fusions are enriched in metastatic, treatment-resistant disease, a small number are present in treatment-na\u00efve tumours, raising the possibility that some act as early drivers of oncogenesis. This review outlines the current knowledge on\n                    <jats:italic>ESR1<\/jats:italic>\n                    fusions, evaluating their mechanisms and clinical relevance. Clarifying which\n                    <jats:italic>ESR1<\/jats:italic>\n                    fusions act as true oncogenic drivers versus incidental events will be critical for refining diagnostics and informing future therapeutic development for oncofusion-driven cancers.\n                  <\/jats:p>","DOI":"10.1038\/s41388-026-03813-w","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:49:16Z","timestamp":1778737756000},"page":"2075-2084","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["ESR1 fusion proteins in breast cancer: distinguishing oncogenic drivers from passenger events"],"prefix":"10.1038","volume":"45","author":[{"given":"Ana-Maria","family":"Gherghelas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1641-7535","authenticated-orcid":false,"given":"Christopher P.","family":"Toseland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"3813_CR1","doi-asserted-by":"publisher","first-page":"e4805","DOI":"10.1371\/journal.pone.0004805","volume":"4","author":"I Ortiz de Mendibil","year":"2009","unstructured":"Ortiz de Mendibil I, Vizmanos JL, Novo FJ. Signatures of selection in fusion transcripts resulting from chromosomal translocations in human cancer. PLoS One. 2009;4:e4805.","journal-title":"PLoS One"},{"key":"3813_CR2","doi-asserted-by":"publisher","first-page":"4487","DOI":"10.1093\/nar\/gkw282","volume":"44","author":"NS Latysheva","year":"2016","unstructured":"Latysheva NS, Babu MM. Discovering and understanding oncogenic gene fusions through data intensive computational approaches. Nucleic Acids Res. 2016;44:4487\u2013503.","journal-title":"Nucleic Acids Res"},{"key":"3813_CR3","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.dnarep.2006.05.029","volume":"5","author":"S Agarwal","year":"2006","unstructured":"Agarwal S, Tafel AA, Kanaar R. DNA double-strand break repair and chromosome translocations. DNA Repair. 2006;5:1075\u201381.","journal-title":"DNA Repair"},{"key":"3813_CR4","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1080\/14737159.2016.1220835","volume":"16","author":"FG Barr","year":"2016","unstructured":"Barr FG. Fusion genes in solid tumors: the possibilities and the pitfalls. Expert Rev Mol Diagn. 2016;16:921\u20133.","journal-title":"Expert Rev Mol Diagn"},{"key":"3813_CR5","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/jcb.21481","volume":"102","author":"P Gasparini","year":"2007","unstructured":"Gasparini P, Sozzi G, Pierotti MA. The role of chromosomal alterations in human cancer development. J Cell Biochem. 2007;102:320\u201331.","journal-title":"J Cell Biochem"},{"key":"3813_CR6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nrc2091","volume":"7","author":"F Mitelman","year":"2007","unstructured":"Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer. 2007;7:233\u201345.","journal-title":"Nat Rev Cancer"},{"key":"3813_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2011-12-1-r6","volume":"12","author":"H Edgren","year":"2011","unstructured":"Edgren H, Murumagi A, Kangaspeska S, Nicorici D, Hongisto V, Kleivi K, et al. Identification of fusion genes in breast cancer by paired-end RNA-sequencing. Genome Biol. 2011;12:R6.","journal-title":"Genome Biol"},{"key":"3813_CR8","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1158\/1535-7163.MCT-09-0135","volume":"8","author":"FJ Kaye","year":"2009","unstructured":"Kaye FJ. Mutation-associated fusion cancer genes in solid tumors. Mol Cancer Ther. 2009;8:1399\u2013408.","journal-title":"Mol Cancer Ther"},{"key":"3813_CR9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S1535-6108(02)00180-0","volume":"2","author":"C Tognon","year":"2002","unstructured":"Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, Mathers JA, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002;2:367\u201376.","journal-title":"Cancer Cell"},{"key":"3813_CR10","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1038\/nm.2580","volume":"17","author":"DR Robinson","year":"2011","unstructured":"Robinson DR, Kalyana-Sundaram S, Wu YM, Shankar S, Cao X, Ateeq B, et al. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med. 2011;17:1646\u201351.","journal-title":"Nat Med"},{"key":"3813_CR11","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/ijc.29825","volume":"138","author":"JS Ross","year":"2016","unstructured":"Ross JS, Wang K, Chmielecki J, Gay L, Johnson A, Chudnovsky J, et al. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. Int J Cancer. 2016;138:881\u201390.","journal-title":"Int J Cancer"},{"key":"3813_CR12","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.annonc.2020.04.008","volume":"31","author":"DS Ross","year":"2020","unstructured":"Ross DS, Liu B, Schram AM, Razavi P, Lagana SM, Zhang Y, et al. Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients. Ann Oncol. 2020;31:991\u20131000.","journal-title":"Ann Oncol"},{"key":"3813_CR13","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/ng.2823","volume":"45","author":"DR Robinson","year":"2013","unstructured":"Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45:1446\u201351.","journal-title":"Nat Genet"},{"key":"3813_CR14","doi-asserted-by":"crossref","unstructured":"Clusan L, Le Goff P, Flouriot G, Pakdel F. A closer look at estrogen receptor mutations in breast cancer and their implications for estrogen and antiestrogen responses. Int J Mol Sci. 2021;22:756.","DOI":"10.3390\/ijms22020756"},{"key":"3813_CR15","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s00109-021-02136-5","volume":"99","author":"O Saatci","year":"2021","unstructured":"Saatci O, Huynh-Dam KT, Sahin O. Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies. J Mol Med. 2021;99:1691\u2013710.","journal-title":"J Mol Med"},{"key":"3813_CR16","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.celrep.2013.08.022","volume":"4","author":"S Li","year":"2013","unstructured":"Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 2013;4:1116\u201330.","journal-title":"Cell Rep"},{"key":"3813_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5577","volume":"5","author":"J Veeraraghavan","year":"2014","unstructured":"Veeraraghavan J, Tan Y, Cao XX, Kim JA, Wang X, Chamness GC, et al. Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers. Nat Commun. 2014;5:4577.","journal-title":"Nat Commun"},{"key":"3813_CR18","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/j.celrep.2018.07.009","volume":"24","author":"JT Lei","year":"2018","unstructured":"Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, et al. Functional annotation of ESR1 gene fusions in estrogen receptor-positive breast cancer. Cell Rep. 2018;24:1434\u201344.e7.","journal-title":"Cell Rep"},{"key":"3813_CR19","doi-asserted-by":"publisher","first-page":"6259","DOI":"10.1158\/0008-5472.CAN-21-1256","volume":"81","author":"X Gou","year":"2021","unstructured":"Gou X, Anurag M, Lei JT, Kim BJ, Singh P, Seker S, et al. Transcriptional reprogramming differentiates active from inactive ESR1 fusions in endocrine therapy-refractory metastatic breast cancer. Cancer Res. 2021;81:6259\u201372.","journal-title":"Cancer Res"},{"key":"3813_CR20","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/oncolo\/oyac248","volume":"28","author":"JO Brett","year":"2023","unstructured":"Brett JO, Ritterhouse LL, Newman ET, Irwin KE, Dawson M, Ryan LY, et al. Clinical implications and treatment strategies for ESR1 fusions in hormone receptor-positive metastatic breast cancer: a case series. Oncologist. 2023;28:172\u20139.","journal-title":"Oncologist"},{"key":"3813_CR21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/gcc.23029","volume":"61","author":"SK Loo","year":"2022","unstructured":"Loo SK, Yates ME, Yang S, Oesterreich S, Lee AV, Wang XS. Fusion-associated carcinomas of the breast: diagnostic, prognostic, and therapeutic significance. Genes Chromosomes Cancer. 2022;61:261\u201373.","journal-title":"Genes Chromosomes Cancer"},{"key":"3813_CR22","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nrc3947","volume":"15","author":"F Mertens","year":"2015","unstructured":"Mertens F, Johansson B, Fioretos T, Mitelman F. The emerging complexity of gene fusions in cancer. Nat Rev Cancer. 2015;15:371\u201381.","journal-title":"Nat Rev Cancer"},{"key":"3813_CR23","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/gcc.22745","volume":"58","author":"B Johansson","year":"2019","unstructured":"Johansson B, Mertens F, Schyman T, Bjork J, Mandahl N, Mitelman F. Most gene fusions in cancer are stochastic events. Genes Chromosomes Cancer. 2019;58:607\u201311.","journal-title":"Genes Chromosomes Cancer"},{"key":"3813_CR24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/boc.201400096","volume":"107","author":"MA Davare","year":"2015","unstructured":"Davare MA, Tognon CE. Detecting and targetting oncogenic fusion proteins in the genomic era. Biol Cell. 2015;107:111\u201329.","journal-title":"Biol Cell"},{"key":"3813_CR25","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.1038\/onc.2014.406","volume":"34","author":"K Yoshihara","year":"2015","unstructured":"Yoshihara K, Wang Q, Torres-Garcia W, Zheng S, Vegesna R, Kim H, et al. The landscape and therapeutic relevance of cancer-associated transcript fusions. Oncogene. 2015;34:4845\u201354.","journal-title":"Oncogene"},{"key":"3813_CR26","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1093\/annonc\/mdy025","volume":"29","author":"RJ Hartmaier","year":"2018","unstructured":"Hartmaier RJ, Trabucco SE, Priedigkeit N, Chung JH, Parachoniak CA, Vanden Borre P, et al. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer. Ann Oncol. 2018;29:872\u201380.","journal-title":"Ann Oncol"},{"key":"3813_CR27","doi-asserted-by":"crossref","unstructured":"Lei JT, Gou X, Seker S, Ellis MJ. ESR1 alterations and metastasis in estrogen receptor positive breast cancer. J Cancer Metastasis Treat. 2019;5:38.","DOI":"10.20517\/2394-4722.2019.12"},{"key":"3813_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09265-1","volume":"22","author":"SR Vitale","year":"2022","unstructured":"Vitale SR, Ruigrok-Ritstier K, Timmermans AM, Foekens R, Trapman-Jansen A, Beaufort CM, et al. The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer. BMC Cancer. 2022;22:165.","journal-title":"BMC Cancer"},{"key":"3813_CR29","doi-asserted-by":"crossref","unstructured":"Yates ME, Li Z, Li Y, Guzolik H, Wang X, Liu T, et al. ESR1 fusion proteins invoke breast cancer subtype-dependent enrichment of ligand independent pro-oncogenic signatures and phenotypes. bioRxiv. 2023. https:\/\/www.biorxiv.org\/content\/10.1101\/2023.09.18.558175v1.full.","DOI":"10.1101\/2023.09.18.558175"},{"key":"3813_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01325-3","volume":"22","author":"L Li","year":"2020","unstructured":"Li L, Lin L, Veeraraghavan J, Hu Y, Wang X, Lee S, et al. Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance. Breast Cancer Res. 2020;22:84.","journal-title":"Breast Cancer Res"},{"key":"3813_CR31","doi-asserted-by":"crossref","unstructured":"Jeong JH, Yun JW, Kim HY, Heo CY, Lee S. Elucidation of novel therapeutic targets for breast cancer with ESR1-CCDC170 fusion. J Clin Med. 2021;10;582.","DOI":"10.3390\/jcm10040582"},{"key":"3813_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1037531","volume":"12","author":"Z Nagy","year":"2022","unstructured":"Nagy Z, Jeselsohn R. ESR1 fusions and therapeutic resistance in metastatic breast cancer. Front Oncol. 2022;12:1037531.","journal-title":"Front Oncol"},{"key":"3813_CR33","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10549-016-3876-y","volume":"158","author":"J Veeraraghavan","year":"2016","unstructured":"Veeraraghavan J, Ma J, Hu Y, Wang XS. Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications. Breast Cancer Res Treat. 2016;158:219\u201332.","journal-title":"Breast Cancer Res Treat"},{"key":"3813_CR34","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/nature08645","volume":"462","author":"Stephens","year":"2009","unstructured":"Stephens, McBride PJ, Lin DJ, Varela ML, Pleasance I, Simpson JT ED, et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature. 2009;462:1005\u201310.","journal-title":"Nature"},{"key":"3813_CR35","doi-asserted-by":"crossref","unstructured":"Giltnane JM, Hutchinson KE, Stricker TP, Formisano L, Young CD, Estrada MV, et al. Genomic profiling of ER(+) breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Sci Transl Med. 2017;9:eaai7993.","DOI":"10.1126\/scitranslmed.aai7993"},{"key":"3813_CR36","doi-asserted-by":"crossref","unstructured":"Soutoglou E, Misteli T. On the contribution of spatial genome organization to cancerous chromosome translocations. J Natl Cancer Inst Monogr. 2008;39:16\u20139.","DOI":"10.1093\/jncimonographs\/lgn017"},{"key":"3813_CR37","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.dnarep.2006.05.020","volume":"5","author":"Y Zhang","year":"2006","unstructured":"Zhang Y, Rowley JD. Chromatin structural elements and chromosomal translocations in leukemia. DNA Repair. 2006;5:1282\u201397.","journal-title":"DNA Repair"},{"key":"3813_CR38","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/ncb1591","volume":"9","author":"E Soutoglou","year":"2007","unstructured":"Soutoglou E, Dorn JF, Sengupta K, Jasin M, Nussenzweig A, Ried T, et al. Positional stability of single double-strand breaks in mammalian cells. Nat Cell Biol. 2007;9:675\u201382.","journal-title":"Nat Cell Biol"},{"key":"3813_CR39","doi-asserted-by":"publisher","first-page":"e44196","DOI":"10.1371\/journal.pone.0044196","volume":"7","author":"JM Engreitz","year":"2012","unstructured":"Engreitz JM, Agarwala V, Mirny LA. Three-dimensional genome architecture influences partner selection for chromosomal translocations in human disease. PLoS One. 2012;7:e44196.","journal-title":"PLoS One"},{"key":"3813_CR40","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.semcancer.2006.10.008","volume":"17","author":"KJ Meaburn","year":"2007","unstructured":"Meaburn KJ, Misteli T, Soutoglou E. Spatial genome organization in the formation of chromosomal translocations. Semin Cancer Biol. 2007;17:80\u201390.","journal-title":"Semin Cancer Biol"},{"key":"3813_CR41","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/ncb2941","volume":"16","author":"V Roukos","year":"2014","unstructured":"Roukos V, Misteli T. The biogenesis of chromosome translocations. Nat Cell Biol. 2014;16:293\u2013300.","journal-title":"Nat Cell Biol"},{"key":"3813_CR42","doi-asserted-by":"publisher","first-page":"e1002797","DOI":"10.1371\/journal.pcbi.1002797","volume":"8","author":"M Shugay","year":"2012","unstructured":"Shugay M, Ortiz de Mendibil I, Vizmanos JL, Novo FJ. Genomic hallmarks of genes involved in chromosomal translocations in hematological cancer. PLoS Comput Biol. 2012;8:e1002797.","journal-title":"PLoS Comput Biol"},{"key":"3813_CR43","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ceb.2013.02.015","volume":"25","author":"V Roukos","year":"2013","unstructured":"Roukos V, Burman B, Misteli T. The cellular etiology of chromosome translocations. Curr Opin Cell Biol. 2013;25:357\u201364.","journal-title":"Curr Opin Cell Biol"},{"key":"3813_CR44","doi-asserted-by":"publisher","first-page":"E3649","DOI":"10.1073\/pnas.1602025113","volume":"113","author":"MA Hogenbirk","year":"2016","unstructured":"Hogenbirk MA, Heideman MR, de Rink I, Velds A, Kerkhoven RM, Wessels LF, et al. Defining chromosomal translocation risks in cancer. Proc Natl Acad Sci USA. 2016;113:E3649\u201356.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3813_CR45","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nrc3537","volume":"13","author":"SF Bunting","year":"2013","unstructured":"Bunting SF, Nussenzweig A. End-joining, translocations and cancer. Nat Rev Cancer. 2013;13:443\u201354.","journal-title":"Nat Rev Cancer"},{"key":"3813_CR46","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.cell.2009.04.034","volume":"137","author":"TH Rabbitts","year":"2009","unstructured":"Rabbitts TH. Commonality but diversity in cancer gene fusions. Cell. 2009;137:391\u20135.","journal-title":"Cell"},{"key":"3813_CR47","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1158\/1078-0432.CCR-12-3667","volume":"20","author":"CS Osborne","year":"2014","unstructured":"Osborne CS. Molecular pathways: transcription factories and chromosomal translocations. Clin Cancer Res. 2014;20:296\u2013300.","journal-title":"Clin Cancer Res"},{"key":"3813_CR48","doi-asserted-by":"publisher","DOI":"10.1200\/PO.24.00038","volume":"8","author":"J Ahmed","year":"2024","unstructured":"Ahmed J, Torrado C, Chelariu A, Kim SH, Ahnert JR. Fusion challenges in solid tumors: shaping the landscape of cancer care in precision medicine. JCO Precis Oncol. 2024;8:e2400038.","journal-title":"JCO Precis Oncol"},{"key":"3813_CR49","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/nrclinonc.2017.127","volume":"14","author":"AM Schram","year":"2017","unstructured":"Schram AM, Chang MT, Jonsson P, Drilon A. Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. Nat Rev Clin Oncol. 2017;14:735\u201348.","journal-title":"Nat Rev Clin Oncol"},{"key":"3813_CR50","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ebiom.2017.06.024","volume":"22","author":"P Jiang","year":"2017","unstructured":"Jiang P, Li Y, Poleshko A, Medvedeva V, Baulina N, Zhang Y, et al. The protein encoded by the CCDC170 breast cancer gene functions to organize the golgi-microtubule network. EBioMedicine. 2017;22:28\u201343.","journal-title":"EBioMedicine"},{"key":"3813_CR51","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/nbt.1584","volume":"27","author":"XS Wang","year":"2009","unstructured":"Wang XS, Prensner JR, Chen G, Cao Q, Han B, Dhanasekaran SM, et al. An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. Nat Biotechnol. 2009;27:1005\u201311.","journal-title":"Nat Biotechnol"},{"key":"3813_CR52","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/ng1215","volume":"34","author":"DG Albertson","year":"2003","unstructured":"Albertson DG, Collins C, McCormick F, Gray JW. Chromosome aberrations in solid tumors. Nat Genet. 2003;34:369\u201376.","journal-title":"Nat Genet"},{"key":"3813_CR53","doi-asserted-by":"publisher","first-page":"e1000552","DOI":"10.1371\/journal.pcbi.1000552","volume":"5","author":"H Hegyi","year":"2009","unstructured":"Hegyi H, Buday L, Tompa P. Intrinsic structural disorder confers cellular viability on oncogenic fusion proteins. PLoS Comput Biol. 2009;5:e1000552.","journal-title":"PLoS Comput Biol"},{"key":"3813_CR54","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.str.2018.10.026","volume":"27","author":"Y Peng","year":"2019","unstructured":"Peng Y, Cao S, Kiselar J, Xiao X, Du Z, Hsieh A, et al. A metastable contact and structural disorder in the estrogen receptor transactivation domain. Structure. 2019;27:229\u201340.e4.","journal-title":"Structure"},{"key":"3813_CR55","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41594-020-00550-w","volume":"28","author":"S Terlecki-Zaniewicz","year":"2021","unstructured":"Terlecki-Zaniewicz S, Humer T, Eder T, Schmoellerl J, Heyes E, Manhart G, et al. Biomolecular condensation of NUP98 fusion proteins drives leukemogenic gene expression. Nat Struct Mol Biol. 2021;28:190\u2013201.","journal-title":"Nat Struct Mol Biol"},{"key":"3813_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21690-7","volume":"12","author":"L Zuo","year":"2021","unstructured":"Zuo L, Zhang G, Massett M, Cheng J, Guo Z, Wang L, et al. Loci-specific phase separation of FET fusion oncoproteins promotes gene transcription. Nat Commun. 2021;12:1491.","journal-title":"Nat Commun"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03813-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03813-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03813-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T22:02:14Z","timestamp":1780005734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03813-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":56,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2026,6,19]]}},"alternative-id":["3813"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03813-w","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"16 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}